SYRE

Stats

Summary

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f

Market Cap: 1.46 Billion

Primary Exchange: NASDAQ

Website: aegleabio.com

Shares Outstanding: 36.2 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 2.0318390762072056

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 29 trading days

From: 2024-01-30 To: 2024-02-29

Lowest Point: